Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Finalizes Acquisition Of Nanjing Meirui For $70 Million

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - GlaxoSmithKline announced that the company has reached an agreement to acquire urology-dedicated Nanjing MeiRui in China for $70 million to expand its urology and over-the-counter presence in China's booming pharmaceutical market

You may also be interested in...



GSK Buys Out Neptunus Stake in Chinese Vaccines JV; Are New Pharmacopoeia Standards At Play?

In an effort to increase its footprint in the Chinese vaccine market, GlaxoSmithKline PLC will acquire the remaining 51% equity stake in its joint venture with China's Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. for $39 million in cash, the companies announced June 14

GSK Buys Out Neptunus Stake in Chinese Vaccines JV; Are New Pharmacopoeia Standards At Play?

In an effort to increase its footprint in the Chinese vaccine market, GlaxoSmithKline PLC will acquire the remaining 51% equity stake in its joint venture with China's Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. for $39 million in cash, the companies announced June 14

GSK Buys Out Partner Neptunus' Stake in Chinese Vaccines Joint Venture

New Chinese Pharmacopoeia standards that mean increased development spending and longer timelines to launch may be at play.

Related Content

UsernamePublicRestriction

Register

SC073767

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel